Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain.” The patent protects the company’s use of augmented intelligence (AI) in its Nociscan platform, which analyzes magnetic resonance spectroscopy (MRS) data to help physicians identify the location of chronic low back pain.
The newly issued patent covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. It also includes AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This capability aims to ensure consistent, reproducible outputs across different imaging systems and sites, which is a key step toward broader clinical adoption.
“This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice,” said Brent Ness, Chief Executive Officer of Aclarion. “By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent expands Aclarion’s intellectual property portfolio to 64 issued and pending patents worldwide, reinforcing its competitive moat in the chronic low back pain market. Chronic low back pain affects approximately 266 million people globally, and Aclarion’s Nociscan platform, when used alongside other diagnostic tools, has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated, according to clinical data.
Aclarion’s cloud-based Nociscan platform converts complex MRS spectral data into clinically actionable insights, enabling physicians to distinguish between painful and non-painful discs in the spine. The company expects the patent to accelerate its ability to scale by protecting its use of AI in future versions of the platform to further automate biomarker identification, accelerate report generation, and reduce manual quality reviews. The patent can be read at this link.
This development underscores Aclarion’s strategy to build a differentiated, software-driven platform in the underserved chronic low back pain market. The company continues to focus on leveraging MRS, proprietary signal processing, biomarkers, and augmented intelligence to optimize clinical treatments. For more information about Aclarion and Nociscan, visit www.aclarion.com.
